[Endocrinologic factors in the development of benign prostatic hyperplasia].
The development of benign prostatic hyperplasia is determined by aging and a functioning testis. This concept of the pathogenesis is supported by studies showing that regression of the enlarged prostate can be achieved by means of drugs that interfere with either the synthesis or the action of testosterone. Since both these therapeutic principles lead to symptoms of hypogonadism their therapeutic value is limited. Recent observations, however, indicate the feasibility of developing agents that will relieve the obstruction of urinary outflow and cause shrinkage of the enlarged prostate without impairing the action of androgen in other tissues.
Schweikert
H U
HU
Medizinische Universitäts-Poliklinik Bonn.
Neumann
F
F
Tunn
U W
UW
D000728:Androgens / Q000502:physiology*; D000818:Animals; D004195:Disease Models, Animal; D004285:Dogs; D004967:Estrogens / Q000502:physiology*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000503:physiopathology*
D000728:Androgens; D004967:Estrogens
Endokrinologische Faktoren für die Entstehung der benignen Prostatahyperplasie.